-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Dmw5WfX8fWKBsUiUUeO8z0qFqwIPuoDgRDgyX1P8aZ1y+emqEQ5cdBwHOmoxvrn4 rYKX1Fho1yIXi+y7kRcCXQ== 0001144204-05-012192.txt : 20050420 0001144204-05-012192.hdr.sgml : 20050420 20050420095757 ACCESSION NUMBER: 0001144204-05-012192 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20050415 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20050420 DATE AS OF CHANGE: 20050420 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Chembio Diagnostics Inc. CENTRAL INDEX KEY: 0001092662 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880425691 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30379 FILM NUMBER: 05760775 BUSINESS ADDRESS: STREET 1: 3661 HORSEBLOCK ROAD CITY: MEDFORD STATE: NY ZIP: 11763 BUSINESS PHONE: (631) 924-1135 MAIL ADDRESS: STREET 1: 3661 HORSEBLOCK ROAD CITY: MEDFORD STATE: NY ZIP: 11763 FORMER COMPANY: FORMER CONFORMED NAME: TRADING SOLUTIONS COM INC DATE OF NAME CHANGE: 19990805 8-K 1 v016634form8k.htm Unassociated Document
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 15, 2005

Chembio Diagnostics, Inc.
(Exact name of registrant as specified in its charter)



Nevada
333-85787
88-0425691
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer Identification No.)



3661 Horseblock Road, Medford, NY    11763
(Address of principal executive offices)   (Zip Code)

Registrant's telephone number, including area code (631) 924-1135


N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

ITEM 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Effective April 15, 2005, Mark L. Baum resigned as a member of the Board of Directors of Chembio Diagnostics, Inc. (the “Company”). Mr. Baum’s resignation was not a result of any disagreement with the Company. On April 20, 2005, the Company issued a press release announcing Mr. Baum’s resignation. A copy of the press release is attached hereto as Exhibit 99.1.

Effective April 15, 2005, the Company’s Board of Directors elected Alan Carus to become a member of the Board of Directors. Mr. Carus is a co-founder of LARC Strategic Concepts LLC, a consulting firm dedicated to guiding emerging companies to next stage development. Prior to co-founding LARC Strategic Concepts LLC, Mr. Carus was Senior Vice President of Maritime Overseas Corporation (“MOC”) and a senior executive of Overseas Shipholding Group, Inc. (“OSG”) from 1981 to 1998, when he retired. MOC was managing agent for OSG, one of the world’s largest ship-owners. Mr. Carus was a member of OSG’s senior management committee and had senior responsibility in areas relating to administration, accounting, tax, finance, budgets, long-range projections, and human resources. He was involved in numerous acquisitions, debt and equity offerings, complex transaction structuring, and was active in the management of OSG’s major investments in the cruise industry and other development stage companies. From 1964 to 1981, Mr. Carus was with Ernst & Young (including predecessors), the last seven years as a partner. Mr. Carus has a B.B.A. from the Baruch School of Business of the City College of New York.

Mr. Carus’ election to the Board of Directors also was announced in the press release attached hereto as Exhibit 99.1.

ITEM 9.01. Financial Statements and Exhibits

(c) Exhibits

99.1 Press release dated April 20, 2005

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
     
  CHEMBIO DIAGNOSTICS, INC.
 
 		  
 		  
 
Date: April 20, 2005 By:   /s/ Lawrence A. Siebert
 
Lawrence A. Siebert
 
Chief Executive Officer
 EX-99.1 2 ex-99_1.htm Unassociated Document

Chembio Diagnostics Appoints Alan Carus to its Board of Directors

MEDFORD, N.Y.--(BUSINESS WIRE)—April 19, 2005--Chembio Diagnostics, Inc. (OTCBB: CEMI) announced today that it has elected Alan Carus as an independent member of its Board of Directors. Mr. Carus is a co-founder of LARC Strategic Concepts LLC, a consulting firm dedicated to guiding emerging companies to next stage development. Prior to co-founding LARC Strategic Concepts LLC, Mr. Carus was Senior Vice President of Maritime Overseas Corporation and a senior executive of Overseas Shipholding Group, Inc. (OSG), one of the world’s largest ship-owners, from 1981 to 1998, when he retired. The Company also announced that Mark L. Baum resigned as a member of the Board of Directors. Mr. Baum’s resignation was not a result of any disagreement with the Company.
 
While at OSG, Mr. Carus was a member of the senior management committee and had senior responsibility relating to administration, accounting, tax, finance, budgets, long-range projections, and human resources. He was involved in numerous acquisitions, debt and equity offerings, complex transaction structuring, and was active in the management of OSG’s major investments in the cruise industry and other development stage companies. Mr. Carus is a former partner of the accounting firm Ernst & Young (including predecessor firms). He has a B.B.A. from the Baruch School of Business of the City College of New York.

“I am pleased that Alan has agreed to join our Board of Directors,” said Lawrence A. Siebert, Chembio Diagnostic’s President. “His business experience should help us as we continue to expand the customer base for our suite of rapid test products. I would also like to thank Mark for his service on the Board and his role in helping the Company further advance its business and capitalization.”
 
ABOUT CHEMBIO
 
Chembio Diagnostics, Inc. (Chembio) possesses expertise in the development and manufacturing of rapid test products for various indications, including HIV, Tuberculosis and BSE (a.k.a. Mad Cow Disease). References to Chembio Diagnostics, Inc. may actually refer to Chembio Diagnostic Systems, Inc., the 100%-owned subsidiary of Chembio Diagnostics, Inc. Chembio is located at 3661 Horseblock Road, Medford, NY 11763. Chembio's telephone number is 631-924-1135. Email can be directed to info@chembio.com. Additional information can be found at www.chembio.com.
 
 
FORWARD-LOOKING STATEMENTS
 
Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing and the demand for the Company's products. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC").
 
_____________
Contact: 
CEOcast, Inc. for Chembio Diagnostics
Ed Lewis, 212-732-4300, ext. 225




 -----END PRIVACY-ENHANCED MESSAGE-----